Press Releases
Press Releases
Dec 04, 2023
Nov 06, 2023
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
Nov 06, 2023
Sep 27, 2023
CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
Sep 07, 2023
Aug 07, 2023
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
Jun 13, 2023
CRISPR Therapeutics to Participate in Goldman Sachs 44th Annual Global Healthcare Conference
May 08, 2023
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
Mar 14, 2023
CRISPR Therapeutics to Present at the American Association for Cancer Research 2023 Annual Meeting
Feb 21, 2023
Jan 11, 2023
CRISPR Therapeutics to Participate in B. Riley Securities’ 3rd Annual Oncology Conference
Dec 19, 2022
Dec 10, 2022
Nov 10, 2022
Nov 01, 2022
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
Oct 05, 2022
CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
Sep 29, 2022
CRISPR Therapeutics to Present at the BMO Biopharma Spotlight Series: Gene Editing and Therapy
Aug 08, 2022
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results
Jun 08, 2022
CRISPR Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
May 16, 2022
May 09, 2022
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results
Mar 08, 2022
Feb 15, 2022
Feb 09, 2022
CRISPR Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
Nov 03, 2021
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results
Oct 01, 2021
Sep 28, 2021
CRISPR Therapeutics to Participate in the Chardan’s 5th Annual Genetic Medicines Conference
Aug 05, 2021
CRISPR Therapeutics to Participate in the Canaccord Genuity 41st Annual Growth Conference
Jul 29, 2021
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results
May 06, 2021
Apr 27, 2021
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results
Apr 06, 2021
CRISPR Therapeutics to Participate in the 20th Annual Needham Virtual Healthcare Conference
Mar 10, 2021
Feb 16, 2021
Feb 05, 2021
CRISPR Therapeutics to Participate in the Guggenheim Healthcare Talks 2021 Oncology Day
Feb 01, 2021
CRISPR Therapeutics Announces the Appointment of Philippe Drouet as Chief Commercial Officer
Dec 14, 2020
CRISPR Therapeutics Receives Grant to Advance In Vivo CRISPR/Cas9 Gene Editing Therapies for HIV
Nov 24, 2020
CRISPR Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
Nov 16, 2020
CRISPR Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference
Oct 28, 2020
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2020 Financial Results
Oct 07, 2020
Jul 27, 2020
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2020 Financial Results
May 15, 2020
May 07, 2020
CRISPR Therapeutics to Present at the Bank of America Securities 2020 Health Care Conference
Apr 28, 2020
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2020 Financial Results
Feb 12, 2020
Oct 28, 2019
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2019 Financial Results
Jul 29, 2019
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2019 Financial Results
Apr 29, 2019
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2019 Financial Results
Apr 16, 2019
Feb 27, 2019
Feb 25, 2019
Nov 09, 2018
CRISPR Therapeutics and MaxCyte Expand Clinical and Commercial License Agreement into Oncology
Nov 07, 2018
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2018 Financial Results
Aug 07, 2018
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2018 Financial Results
Aug 07, 2018
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2018 Financial Results
May 08, 2018
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2018 Financial Results
Apr 16, 2018
Apr 13, 2018
CRISPR Therapeutics to Present Data on Allogeneic CRISPR-based CAR-T Cell Therapies at AACR 2018
Apr 04, 2018
CRISPR Therapeutics Announces the Appointment of Steve Caffé as Head of Regulatory Affairs
Mar 08, 2018
Nov 13, 2017
CRISPR Therapeutics Announces Appointment of Michael Tomsicek as Chief Financial Officer
Nov 13, 2017
CRISPR Therapeutics and Casebia Collaborate with CureVac on mRNA for Gene-Editing Programs
Nov 08, 2017
CRISPR Therapeutics Announces Third Quarter 2017 Financial Results and Provides Business Update
Oct 02, 2017
CRISPR Therapeutics Announces Promotion of Samarth Kulkarni, Ph.D. to Chief Executive Officer
Aug 10, 2017
CRISPR Therapeutics Announces Second Quarter 2017 Financial Results and Provides Business Update
May 11, 2017
May 08, 2017
CRISPR Therapeutics Announces Exclusive License of Lipid Nanoparticle Technologies Developed at MIT
Apr 26, 2017
Apr 17, 2017
Mar 14, 2017
CRISPR Therapeutics and Casebia Therapeutics Announce Commercial License Agreement With MaxCyte
Mar 10, 2017
Mar 10, 2016
Sep 30, 2015
FierceBiotech names CRISPR Therapeutics as one of its “Fierce 15” Biotech Companies of 2015
Nov 10, 2014

You are now leaving the CRISPR Therapeutics website.
CRISPR Therapeutics is not responsible for the content or availability of third-party sites.